Once seen as a bright hope for immuno-oncology, the reputation of anti-TIGIT checkpoint inhibitors has yet to recover from the double whammy of trial flops that Roche experienced last year. So you can ...
On their most recent earnings call, Roche executives appeared to be giving coded messages about their strategy for anti-TIGIT checkpoint inhibitors. While they dodged questions about whether their ...
Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular ...
PD-1 blockade plus chemotherapy followed by concurrent SBRT with SIB as preoperative therapy for patients with potentially resectable pancreatic cancer: A single-arm phase 2 study. This is an ASCO ...
Scientists at Albert Einstein College of Medicine have developed a new anticancer strategy that they suggest could bolster the effectiveness of immune-checkpoint therapy. The team said their findings ...
Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "TIGIT Inhibitors - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report presents in-depth insights into more than ...
The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with NSCLC, RCC, colorectal cancer, lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results